Akute lymphatische Leukämie (ALL)
| GMALL Register (07/2003) | RS |
GMALL Register/Biomaterialdatenbank, Prospektive Datenerfassung, |
|
AMG103 |
I/II |
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) |
|
EVOLVE |
Phase II |
A multicentre, randomized trial in adults with de novo Philadelphia- Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate Blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE) |
Akute myeloische Leukämie (AML)
|
Mosaic |
Phase I und II |
Midostaurin + Gemtuzumab Ozogamicin als Erstlinientherapie für Patienten mit |
| SAL Register | RS | AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) und der AML Cooperative Group (AML-CG) |
| Napoleon-Register | RS | akute Promyelozytenleukämie |
Chronische lymphatische Leukämie (CLL)
|
CLL18 |
Phase III |
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab |
|
BGB-11417-303 |
III |
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) |
Chronische myeloische Leukämie (CML)
| BlastCrisis | RS |
Register zur Blastenkrise bei Patienten mit Chronischer Myeloischer Leukämie (CML) |
|
ELVN-001 |
Phase II |
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML) |
| TERN701-1012 | Phase II |
Eine klinische Prüfung der Phase I zur Beurteilung der Sicherheit, Verträglichkeit, |
|
ASCANY |
REGISTER |
Deutsches prospektives Register für Patienten mit chronischer myeloischer Leukämie (CML), |
Hodgkin-Lymphom (HL)
|
PREFer |
Phase II |
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma |
Myelodysplastische Neoplasien (MDS)
Multiples Myelom (MM)
|
DREAMM 10 |
Phase III |
Eine randomisierte, offene Phase-III-Studie zu Belantamab Mafodotin bei Verabreichung in Kombination mit Lenalidomid und Dexamethason (BRd) im Vergleich zu Daratumumab, Lenalidomid und Dexamethason (DRd) bei Teilnehmern mit neu diagnostiziertem multiplem Myelom, die für eine autologe Stammzelltransplantation nicht in Frage kommen (TI-NDMM) |
|
Trilogy-4 |
Phase III |
A Phase 3 Randomized Study Comparing JNJ-79635322 and an anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody |
Myeloproliferative Neoplasien (MPN)
| MPN-SG BiO | RS | Registerstudie zur Erfassung des biologischen Erkrankungsprofils und des klinischen Verlaufs bei Patienten mit BCR-ABL1 negativen myeloischen Neoplasien: Das MPNSG Biology and Outcome (BiO)-Projekt |
|
TL-895-201 |
Phase II |
A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis |
|
POESIS |
Phase III |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib |
Maligne Lymphome (Non-Hodgkin-Lymphom, NHL)
|
CA073-1003 |
Phase III |
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma Eudract Nr. 2024-519152-82 |
|
CLEAR |
II |
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
BGB-16673-104 |
Ib/II |
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
|
|
Soundtrack-B D7404C00001 |
II |
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients |
Sonstige hämatologische Erkrankungen
| HLH- Register für Erwachsene |
RS | Registrierung klinischer Daten und Laborparameter bei hämophagozytischer Lymphohistiozytose (HLH) |